(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/176104 A9

(51) International Patent Classification:
C07D 401/14 (2006.01) *C07D 417/12* (2006.01)
C07D 417/14 (2006.01) *A61P 25/28* (2006.01)
C07D 401/12 (2006.01) *A61K 31/444* (2006.01)

(21) International Application Number:
PCT/CN2025/077757

(22) International Filing Date:
18 February 2025 (18.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/077492
19 February 2024 (19.02.2024) CN

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.** [JP/JP]; 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526 (JP).

(71) Applicant *(for MG only)*: **WUXI APPTEC (SHANGHAI) CO., LTD.** [CN/CN]; Building No. 1, 288 Fute Zhong Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN).

(72) Inventors: **KODERA, Yasuyo**; c/o ONO PHARMACEUTICAL CO., LTD., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585 (JP). **KAWAMATA, Takahiro**; c/o ONO PHARMACEUTICAL CO., LTD., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585 (JP). **WATANABE, Ryosuke**; c/o ONO PHARMACEUTICAL CO., LTD., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585 (JP).

(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Building 1, 10 Caihefang Road, Haidian District, Beijing 100080 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report (Art. 21(3))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
04 December 2025 (04.12.2025)

(15) Information about Correction:
see Notice of 04 December 2025 (04.12.2025)

WO 2025/176104 A9

(54) Title: HETEROCYCLIC DERIVATIVES HAVING S1P3 RECEPTOR ANTAGONISTIC ACTIVITY



(I)

(57) Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided, which is useful as a pharmaceutical ingredient having $S1P_3$ receptor antagonistic activity in the prevention and/or treatment an $S1P_3$-mediated disease, wherein all symbols represent the same meaning as the symbols described in the specification. A drug is also provided, which containing, as an active ingredient, a compound having $S1P_3$ receptor antagonistic activity in the prevention and/or treatment an $S1P_3$-mediated disease.